Radiometric susceptibility testing of Mycobacterium tuberculosis against second-line drugs.

Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

Radiometric susceptibility testing of Mycobacterium tuberculosis against second-line drugs.

Abstr Gen Meet Am Soc Microbiol. 1994;94:197 (abstract no. U-138). Unique Identifier : AIDSLINE ASM94/94313077
Salfinger M; Gross W; Kornblum J; Laszlo A; Pfyffer G; Roberts G; Siddiqi S; NY State Dept. of Health, Albany.

Abstract: AIDS epidemic, deterioration of the public health infrastructure and inadequate training of health care providers are some factors contributing to the increase of tuberculosis (TB), especially multidrug-resistant TB. In vitro drug susceptibility testing is now required for all TB patients. Since faster turnaround times in the TB laboratory are necessary, we compared the radiometric technique with the conventional Middlebrook 7H10 agar method for susceptibility to second-line drugs in a 3 phase study. In phase I, 10 susceptible M. tuberculosis strains were tested in the BACTEC system against the following drugs and concentration (mcg/ml): amakicin (AN, 1.0, 2.0, 4.0), capreomycin (CM, 1.25, 2.5, 5.0), ciprofloxacin (CIP, 0.5, 1.0, 2.0), clofazimine (CLO, 0.25, 0.5, 1.0), cycloserine (CS, 50, 60, 70), ethionamide (ETA, 1.25, 2.5, 5.0), kanamycin (KM, 1.25, 2.5, 5.0), ofloxacin (OFL, 0.5, 1.0, 2.0, 4.0). In phase II, specially selected 20 isolates with some strains resistant to each drug were tested. Drug concentrations were adjusted based on the results in Phase I. CIP was dropped and rifabutin (RBT, 0.5, 1.0, 2.0) was included. The following preliminary critical concentrations (mcg/ml) for radiometric method were established: AN 1.0, CM 2.5, CLO 0.25, CS 100.0, ETA 1.25, KM 2.5, OFL 2.0, and RBT 1.0. Final recommendations will be made after finishing testing 30-50 recent clinical isolates in phase III.

Keywords: Antibiotics/*TOXICITY AIDS-Related Opportunistic Infections/DRUG THERAPY Capreomycin Sulfate Comparative Study Drug Resistance, Microbial Human Microbial Sensitivity Tests/*METHODS Mycobacterium tuberculosis/*DRUG EFFECTS/GROWTH & DEVELOPMENT/ ISOLATION & PURIF Species Specificity Tuberculosis, Pulmonary/COMPLICATIONS/DRUG THERAPY ABSTRACT
941030
M94A0877

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .